<DOC>
	<DOC>NCT00377936</DOC>
	<brief_summary>The intention of this trial is to evaluate safety and efficacy of a combination treatment of EndoTAG-1 with Gemcitabine versus Gemcitabine monotherapy.</brief_summary>
	<brief_title>EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Inoperable adenocarcinoma of the pancreas Histologic or cytologic confirmation At least 18 years of age Any chemotherapeutical treatment for pancreatic adenocarcinoma before enrollment Major surgery within 4 weeks prior to enrollment Major cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Adenocarcinoma of the pancreas</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Metastatic</keyword>
</DOC>